Pfizer to build its immuno-oncology pipeline through tie-up with Merck KGAA; Agreement terminated
Merck KGAA has enlisted the help of Pfizer Inc. to jointly develop and commercialize its MSB0010718C anti-programmed cell death ligand 1 (PD-L1) antibody currently in clinical trials for various cancers.
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.